• Recent News:   NICE Guidance Recommends HeartFlow Analysis
  • X

Newsroom

Press Releases

2017

  • HeartFlow Announces Four Blue Cross Blue Shield Companies Issue Positive Medical Policies on Non-Invasive HeartFlow® FFRCT Analysis for Coronary Artery Disease. PDF
  • GE Healthcare and HeartFlow Announce Global Cardiovascular Collaboration. PDF
  • HeartFlow Announces American Medical Association Issues Unique Category III CPT® Codes for HeartFlow® FFRCT. PDF
  • HeartFlow Names Former J&J Chairman and CEO William C. Weldon Chairman of the Board. PDF
  • HeartFlow Announces Its Novel, Non-Invasive FFRCT Technology for Coronary Artery Disease Receives Positive Review from Blue Cross Blue Shield. PDF
  • HeartFlow Names Healthcare Industry Veteran Michael Buck as Executive Vice President and Chief Commercial Officer. PDF
  • Siemens Healthineers and HeartFlow Collaborate to Provide Solution That Has Potential to Lower Cardiac Care Costs. PDF
  • NICE Guidance Recommends HeartFlow FFRCT Analysis to Help Determine Cause of Stable Chest Pain in Patients. PDF

 

2016

  • HeartFlow FFRCT Analysis Receives Regulatory Approval in Japan. PDF
  • Providence Health Care Becomes First Canadian Center to Adopt Revolutionary HeartFlow FFRCT Analysis to Assess Coronary Artery Disease. PDF
  • HeartFlow Introduces Next Generation Platform. PDF
  • Technology from HeartFlow Provides Insights to Help Identify Coronary Plaques at Risk of Rupturing. PDF
  • Highmark Health’s VITAL program partners with Allegheny Health Network and HeartFlow to evaluate a novel 3D technology. PDF
  • One-Year PLATFORM Trial Results Reinforce Benefits of the HeartFlow FFRCT Analysis for Assessing Coronary Artery Disease. PDF

 

2015

  • Trial Demonstrates HeartFlow FFRCT Analysis Significantly Lowers Cost of Care, Improves Quality of Life for Coronary Artery Disease. PDF
  • HeartFlow Secures 50th U.S. Patent. PDF
  • PLATFORM Trial Shows HeartFlow FFRCT Analysis Significantly Decreases Unnecessary Invasive Diagnostic Testing for Coronary Artery Disease. PDF
  • Technology Industry Veteran Phil Mui Joins HeartFlow Product & Engineering Team. PDF
  • EuroPCR Late-breaking Trial: FFRCT RIPCORD Study Demonstrates the Impact of HeartFlow FFRCT Analysis on Patient Management. PDF
  • Kent Walker Joins HeartFlow Board of Directors. PDF

 

2014

  • HeartFlow Names New General Counsel to Executive Team. PDF
  • HeartFlow Appoints Former Johnson & Johnson Chairman and CEO William C. Weldon to Board of Directors. PDF
  • HeartFlow Secures De Novo Clearance from the U.S. Food and Drug Administration for Breakthrough FFRCT Technology. PDF
  • HeartFlow Announces Appointment of Several Key Executive Hires. PDF

 

2013

  • Landmark Study of HeartFlow’s New Non-Invasive Diagnostic Test Demonstrates High Diagnostic Performance in Patients with Suspected Coronary Artery Disease. PDF

 

2011

  • EuroPCR Innovation Award. PDF